Tyra Biosciences, Inc.

NasdaqGS:TYRA Stock Report

Market Cap: US$1.7b

Tyra Biosciences Future Growth

Future criteria checks 0/6

Tyra Biosciences's earnings are forecast to decline at 1.8% per annum while its annual revenue is expected to grow at 86.3% per year. EPS is expected to grow by 3.1% per annum.

Key information

-1.8%

Earnings growth rate

3.07%

EPS growth rate

Biotechs earnings growth29.1%
Revenue growth rate86.3%
Future return on equityn/a
Analyst coverage

Good

Last updated15 Sep 2026

Recent future growth updates

Recent updates

Seeking Alpha • Sep 06

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Summary Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, create significant near-term binary risk and opportunity for the company. Company's SNAP platform enables selective FGFR3 targeting, aiming to address efficacy and tolerability gaps left by pan-FGFR inhibitors. With $353.9M in cash and a burn rate funding operations into 2H 2028, company is financially positioned for upcoming catalysts but faces pivotal clinical risks. Read the full article on Seeking Alpha
Analysis Article • Oct 01

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 28

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 01

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

Summary Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated better safety and tolerability compared to erdafitinib, with fewer high-grade toxicities and lower incidence of hyperphosphatemia and other side effects. Financially, Tyra has a market cap of $632mn, a cash balance of $360mn, and a cash runway of 11–20 quarters, depending on expenses. The market's reaction to TYRA-300's data was mixed; further data from the SURF301 trial is needed to make a definitive investment decision. Read the full article on Seeking Alpha
Seeking Alpha • Dec 17

The Take On Tyra Biosciences

Summary Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg. TYRA-300 aims to overcome limitations of existing mUC therapies like Balversa, with ongoing trials at higher 120mg doses and other cancer/genetic indications. Despite safety concerns, analysts remain bullish on Tyra, with unanimous Buy ratings and price targets between $28 and $33 per share. RA Capital Management increased its stake in Tyra, signaling confidence, but the path to first-line therapy approval remains uncertain pending further data. An analysis around Tyra Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Dec 11

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 21

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights Tyra Biosciences' estimated fair value is US$25.61 based on 2 Stage Free Cash Flow to Equity Tyra...
Seeking Alpha • Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Summary Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024. TYRA has a strong cash position, with $373.8 million as of June 30, 2024, sufficient to fund operations into 2026. Read the full article on Seeking Alpha
Analysis Article • Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 23

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Summary Tyra Biosciences, Inc. has no revenue or earnings, but share prices have increased by 32.68% in the past year. The company focuses on precision medicines targeting FGFR biology, with future promise in oncology and genetic conditions. Despite bullish signals, the lack of key fundamentals makes Tyra a speculative play, rated as a Hold with potential for growth. Read the full article on Seeking Alpha
Analysis Article • Jul 05

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights The projected fair value for Tyra Biosciences is US$18.25 based on 2 Stage Free Cash Flow to Equity Tyra...
Analysis Article • May 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Earnings and Revenue Growth Forecasts

NasdaqGS:TYRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282-247-4-19711
12/31/2027N/A-211-80-17612
12/31/2026N/A-178-69-13312
6/30/2026N/A-149-110-110N/A
3/31/2026N/A-131-102-102N/A
12/31/2025N/A-120-95-95N/A
9/30/2025N/A-112-91-91N/A
6/30/2025N/A-106-87-87N/A
3/31/2025N/A-96-74-73N/A
12/31/2024N/A-86-70-70N/A
9/30/2024N/A-84-65-64N/A
6/30/2024N/A-81-64-63N/A
3/31/2024N/A-75-63-62N/A
12/31/2023N/A-69-51-50N/A
9/30/2023N/A-59-49-49N/A
6/30/2023N/A-51-44-44N/A
3/31/2023N/A-52-52-51N/A
12/31/2022N/A-55-51-50N/A
9/30/2022N/A-52-48-47N/A
6/30/2022N/A-46-42-41N/A
3/31/2022N/A-37-29-28N/A
12/31/2021N/A-26-24-24N/A
9/30/2021N/A-20-18-17N/A
6/30/2021N/A-16-14-14N/A
3/31/2021N/A-12-11-11N/A
12/31/2020N/A-9-8-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TYRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TYRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TYRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TYRA is forecast to have no revenue next year.

High Growth Revenue: TYRA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TYRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/16 21:51
End of Day Share Price 2026/09/16 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tyra Biosciences, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
"Eliana MerleBarclays
Jason ZemanskyBofA Global Research